ABSTRACT
Gravity differs from all other known fundamental forces because it is best described as a curvature of space-time. For that reason, it remains resistant to unifications with quantum theory. Gravitational interaction is fundamentally weak and becomes prominent only at macroscopic scales. This means, we do not know what happens to gravity in the microscopic regime where quantum effects dominate and whether quantum coherent effects of gravity become apparent. Levitated mechanical systems of mesoscopic size offer a probe of gravity, while still allowing quantum control over their motional state. This regime opens the possibility of table-top testing of quantum superposition and entanglement in gravitating systems. Here, we show gravitational coupling between a levitated submillimeter-scale magnetic particle inside a type I superconducting trap and kilogram source masses, placed approximately half a meter away. Our results extend gravity measurements to low gravitational forces of attonewton and underline the importance of levitated mechanical sensors.
ABSTRACT
Metabolite-weighted chemical exchange saturation transfer MRI can be used to indirectly image metabolites such as creatine and glutamate. This study aims to further explore the contrast of CEST at 2 ppm in the human brain at 7T and investigate the metabolite correlates of CEST at 2 ppm via correlations with magnetic resonance spectroscopy (MRS). Simulations were performed to establish the optimal acquisition parameters, such as total saturation time (tsat) and B1 root mean squared (B1rms) for CEST at 2 ppm in the human brain. Parameters were validated via in vitro phantom studies at 7T using concentrations, pH and temperature comparable to what is found in the human brain. Finally, 10 healthy volunteers were scanned at 7T for comparison with MRS. Our results show that the optimal parameters to acquire CEST at 2 ppm images are: B1rms = 2.14 µT & tsat = 1500 ms, respectively. Comparison with MRS showed no significant correlation between CEST at 2 ppm and total Creatine measured by MRS (R = 0.19; p-value = 0.273). However, a significant correlation was found between CEST at 2 ppm and Glu (R = 0.39; p-value = 0.033), indicating the broad Glutamate-weighted CEST as the main measurable contributor to CEST at 2 ppm. We identified and confirmed optimal CEST at 2 ppm sequence parameters and validated CEST at 2 ppm measurements in a controlled in vitro environment. Our findings suggest that glutamate is a substantial contributor to the CEST at 2 ppm contrast observed in the human brain, whereas the creatine contribution to CEST at 2 ppm in the brain did not show a measurable contribution.
